Pre-made Oral Steroid Liquid Letrozole Femara 5mg/ml
Product Details:
Femara 5 Information | ||
Femara 5 Price | 100ml | According to your needs |
500ml | According to your needs | |
1000ml | According to your needs | |
Steroid packaging | Special stealth packaging through Customs | |
Delivery time | About 7 days | |
Shipping | EMS, Hongkong Post, DHL, TNT, Fedex | |
Payment terms | WU, MG, Bitcoin, T/T | |
Minimum order | 100ml liquid |
Pre-made Oral Steroid Liquid Letrozole Femara 5mg/ml
Oral Letrozole (Femara) 5 Details:
Letrozole CAS: 112809-51-5
Letrozole Molecular Formula: C17H11N5
Letrozole Molecular Weight: 285.31
Letrozole Molecular Specifications:5mg/ml
Letrozole White or light yellow Liquid
Letrozole Usage: Used as API in Treatment of breast disease.
Letrozole is approved by the united states food and drug administration (fda) for the treatment of local or metastatic breast cancer that is hormone receptor positive or has an unknown receptor status in postmenopausal women. Letrozole is intended for use only by women who are no longer of childbearing age. Possible candidates must have already ceased to menstruate. It is often used in patients who have already undergone other cancer treatments, such as radiation, chemotherapy, and used other cancer drugs. This nonsteroidal aromatase inhibitor may help prevent any remaining cancer cells from spreading.
Oral Letrozole (Femara) 5 Specifications:
COA
Tests | Specifications | Results |
Appearance | White or off-white crystaline powder | White Crystalline powder |
Solubility | Soluble in Chloroform; Soluble in ethanol when heated | Conform |
ldentification | (1)Maximum absorption in wavelength of 240 nm Minimum absorption in wavelength of 215 nm | Conform Conform |
(2)Infrared spectrum should be in accordance the dominant peak of contrast | In accordance with the dominant peak of contrast | |
Melting points | 182ºC-184ºC | 182ºC |
Related substances | ≤0.5% | 0.3% |
Single impurity | ≤0.3% | 0.2% |
Loss on drying | ≤1.0% | 0.8% |
Assay | ≥98.0% | 99.2% |
Oral Letrozole (Femara) 5 Descriptions:
Letrozole is approved by the united states food and drug administration (fda) for the treatment of local or metastatic breast cancer that is hormone receptor positive or has an unknown receptor status in postmenopausal women.
Letrozole is intended for use only by women who are no longer of childbearing age. Possible candidates must have already ceased to menstruate. It is often used in patients who have already undergone other cancer treatments, such as radiation, chemotherapy, and used other cancer drugs. This nonsteroidal aromatase inhibitor may help prevent any remaining cancer cells from spreading.